title: [Malignant lymphoma: individualized treatment according to biological and clinical risk factors].
authors: Klinikum der Universität München, Campus Großhadern, Medizinische Klinik III, Marchioninistraße 15, 81377 München, Martin.Dreyling@med.uni-muenchen.de
authors: M
authors: M
authors: Dreyling
mesh_terms: D000367:Age Factors; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001688:Biological Products / Q000008:administration & dosage* / Q000009:adverse effects; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors; D008223:Lymphoma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000401:mortality; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality; D057285:Precision Medicine; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D000069283:Rituximab; D015996:Survival Rate; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy / Q000401:mortality
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D001688:Biological Products; D001897:Boronic Acids; D017730:Ki-1 Antigen; D011719:Pyrazines; D003561:Cytarabine; D000069283:Rituximab; D000069286:Bortezomib